Galaxy Biomedical Investment Co., Ltd. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was CNY 1,528 million compared to CNY 1,144.04 million a year ago. Net loss was CNY 337.51 million compared to CNY 965.75 million a year ago.

Basic loss per share from continuing operations was CNY 0.3069 compared to CNY 0.878 a year ago. Diluted loss per share from continuing operations was CNY 0.3069 compared to CNY 0.878 a year ago.